Abstract: Pharmaceutical compositions and methods are provided for treating diabetes and/or restoring ?-cell mass and function in a mammal in need thereof. Type 1 diabetes mellitus (T1 DM) is an autoimmune disorder characterized by immune damage to pancreatic beta-cells. Lisofylline analogs (LSF analogs) are immunomodulators that reduce interlukin 12 signaling and reduce the onset of T1 DM in non-obese diabetic (NOD) mice. A combination therapy with both LSF analog (pretreatment) and INGAP provides protection from autoimmune destruction. The concomitant or combination of an LSF analog and INGAP after pre-treatment with an LSF analog is an effective therapy for a disease or condition resulting from the loss of pancreatic islet cells or insulin production in a mammal.
Abstract: Pharmaceutical compositions and methods are provided for treating diabetes and/or restoring ?-cell mass and function in a mammal in need thereof. Type 1 diabetes mellitus (T1DM) is an autoimmune disorder characterized by immune damage to pancreatic beta-cells. Lisofylline analogs (LSF analogs) are immunomodulators that reduce interlukin 12 signaling and reduce the onset of T1DM in non-obese diabetic (NOD) mice. A combination therapy with both LSF analog (pretreatment) and INGAP provides protection from autoimmune destruction. The concomitant or combination of an LSF analog and INGAP after pre-treatment with an LSF analog is an effective therapy for a disease or condition resulting from the loss of pancreatic islet cells or insulin production in a mammal.
Type:
Application
Filed:
February 2, 2009
Publication date:
March 3, 2011
Applicant:
DIAKINE THERAPEUTICS, INC.
Inventors:
Mary Ann Latona Nadler, Jerry L. Nadler
Abstract: Pharmaceutical compositions and methods are provided for treating diabetes and/or restoring ?-cell mass and function in a mammal in need thereof. Type 1 diabetes mellitus (T1DM) is an autoimmune disorder characterized by immune damage to pancreatic beta-cells. Lisofylline (LSF) is an immunomodulator that reduces cytokine signaling and reduces the onset of T1DM in non-obese diabetic (NOD) mice. A combination therapy with both LSF (pretreatment) and INGAP provides protection from autoimmune destruction. The concomitant or combination of LSF and INGAP after pre-treatment with LSF is an effective therapy for a disease or condition resulting from the loss of pancreatic islet cells or insulin production in a mammal.
Type:
Application
Filed:
February 2, 2009
Publication date:
December 30, 2010
Applicant:
DIAKINE THERAPEUTICS, INC.
Inventors:
Mary Ann Latona Nadler, Jerry L. Nadler
Abstract: An encapsulation system for use in the treatment of diabetes (Types 1 or 2, and LADA) are provided. The system has (1) a delivery vehicle comprising a selectively permeable membrane that allows passage of glucose, insulin and other nutrients through the membrane, but prevents large molecules such as antibodies or inflammatory cells from passing through the membrane; (2) a population of islet cells or insulin producing cells encapsulated by said membrane; and (3) a biological response modifier that may be in contact with the membrane or encapsulated by the membrane.
Abstract: Pharmaceutical compositions and methods for using are provided for restoring ?-cell mass and function in a mammal in need thereof. The pharmaceutical compositions have a biological response modifier and a ?-cell growth factor in admixture with a pharmaceutically acceptable carrier, adjuvant or vehicle.
Abstract: Pharmaceutical compositions and methods for using are provided for restoring ?-cell mass and function in a mammal in need thereof. The pharmaceutical compositions have a biological response modifier and a ?-cell growth factor in admixture with a pharmaceutically acceptable carrier, adjuvant or vehicle.
Abstract: Pharmaceutical compositions and methods for using are provided for restoring ?-cell mass and function in a mammal in need thereof. The pharmaceutical compositions have a biological response modifier and a ?-cell growth factor in admixture with a pharmaceutically acceptable carrier, adjuvant or vehicle.